Ribonucleotide reductase inhibitors: A new look at an old target for radiosensitization

Frontiers in Oncology

Volumn 1, Issue JAN, 2012, Pages

  Chapman, Tobias R ^a   Kinsella, Timothy J ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cervical cancer; Hydroxyurea; Ionizing radiation; Radiosensitizer; Ribonucleotide reductase; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; ALPHA2B INTERFERON; CISPLATIN; DNA; ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; GADOLINIUM TEXAPHYRIN; HYDROXYUREA; PLACEBO; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA REPAIR; DNA SYNTHESIS INHIBITION; DYSPNEA; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IONIZING RADIATION; LEUKOPENIA; METHEMOGLOBINEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER;

EID: 84874642547     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00056     Document Type: Review

References (37)

1. Ahmed, D., and Hassan, H. (2000). Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells. Anticancer Res. 20, 133-138.
2. Argiris, A., Haraf, D., Kies, M., and Vokes, E. (2003). Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil-and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 8, 350-360.
3. Barker, C., Burgan, W., Carter, D., Cerna, D., Gius, D., Hollingshead, M., Camphausen, K., and Tofilon, P. (2006). In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin. Cancer Res. 12, 2912-2918.
4. Beitler, J., Smith, R., Haynes, H., Silver, C., Quish, A., Kotz, T., Serrano, M., Brook, A., and Wadler, S. (1998). A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Invest. New Drugs 16, 161-169.
5. Burkhalter, M., Roberts, S., Havener, J., and Ramsden, D. (2009). Activity of ribonucleotide reductase helps determine how cells repair DNA double strand breaks. DNA Repair (Amst.) 8, 1258-1263.
6. Chabes, A., and Thelander, L. (2000). Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275, 17747-17753.
7. Filatov, D., Bjorklund, S., Johansson, E., and Thelander, L. (1996). Induction of the mouse ribonucleotide reductase R1 and R2 genes in response to DNA damage by UV light. J. Biol. Chem. 271, 23698-23704.
8. Finch, R., Liu, M., Grill, S., Rose, W., Loomis, R., Vazquez, K., Cheng, Y., and Sartorelli, A. (2000). Triapine (3-aminopyridine-2-carboxyaldehyde-thisemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59, 983-991.
9. ®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk. Res. 31, 1165-1173.
10. Guitett, O., Hakansson, P., Voevodskaya, N., Fridd, S., Graslund, A., Arakawa, H., Nakamura, Y., and Thelander, L. (2001). Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276, 40647-40651.
11. Gwilt, P., and Tracewell, W. (1998). Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet. 34, 347-358.
12. Hahn, B., Schrell, U., Sauer, R., Fahlbusch, R., Ganslandt, O., and Grabenbauer, G. (2005). Prolonged oral hydroxyurea and concurrent 3-d conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J. Neurooncol. 74, 157-165.
13. Hashemy, S., Ungerstedt, J., Avval, F., and Holmgren, A. (2006). Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. 281, 10691-10697.
14. Hreshchyshyn, M., Aron, B., Boronow, R., Franklin, E., Shingleton, H., and Blessing, J. (1979). Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int. J. Radiat. Oncol. Biol. Phys. 5, 317-322.
15. Kunos, C., Chiu, S., Pink, J., and Kinsella, T. (2009). Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat. Res. 172, 666-676.
16. Kunos, C., Radivoyevitch, T., Pink, J., Chiu, S., Stefan, T., Jacobberger, J., and Kinsella, T. (2010a). Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat. Res. 174, 574-581.
17. Kunos, C., Waggoner, S., von Greunigen, V., Eldermire, E., Pink, J., Dowlati, A., and Kinsella, T. (2010b). Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin. Cancer Res. 16, 1298-1306.
18. Kuo, M., Hwang, H., Sosnay, P., Kunugi, K., and Kinsella, T. (2003). Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cells reduces radiosensitivity. Cancer J. Sci. Am. 9, 277-285.
19. Kuo, M., and Kinsella, T. (1998). Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 58, 2245-2252.
20. Kuo, M., Kunugi, K., Lindstrom, M., and Kinsella, T. (1997). The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. Cancer J. Sci. Am. 3, 163-173.
21. Mantz, C., Vokes, E., Kies, M., Mittal, B., Witt, M., List, M., Weichselbaum, R., and Haraf, D. (2001). Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann. Oncol. 12, 343-347.
22. Piver, M., Barlow, J., Vongtama, V., and Blumenson, L. (1977). Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am. J. Obstet. Gynecol. 129, 379-383.
23. Piver, M., Howes, A., Suit, H., and Marshall, N. (1972). Effect of hydroxyurea on the radiation response of C3H mouse mammary tumors. Cancer 29, 407-412.
24. Rose, P., Ali, S., Watkins, E., Thigpen, J., Deppe, G., Clarke-Pearson, D., and Insalaco, S. (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 2804-2810.
25. Rose, P., Bundy, B., Watkins, E., Thigpen, J., Deppe, G., Maiman, M., Clarke-Pearson, D., and Insalaco, S. (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340, 1144-1153.
26. Sinclair, W. (1968). The combined effect of hydroxyurea and x-rays on Chinese hamster ovary cells in vitro. Cancer Res. 28, 198-206.
27. Smith, R., Kotz, T., Beitler, J., and Wadler, S. (2000). Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea. Arch. Otolaryngol. Head Neck Surg. 126, 384-389.
28. Stearns, B., Losee, K., and Bernstein, J. (1963). Hydroxyurea. A new type of potential antitumor agent. J. Med. Chem. 6, 201.
29. Symonds, R., Collingwood, M., Kirwan, J., Humber, C., Tierney, J., Green, J., and Williams, C. (2004). Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treat. Rev. 30, 405-414.
30. Szekeres, T., Gharehbaghi, K., Fritzer, M., Woody, M., Srivastava, A., Riet, B., Jayaram, H., and Elford, H. (1994). Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 34, 63-66.
31. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49.
32. Tsimberidou, A., Alvarado, Y., and Giles, F. (2002). Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev. Anticancer Ther. 2, 437-448.
33. Vokes, E., Panje, W., Schilsky, R., Mick, R., Awan, A., Moran, W., Goldman, M., Tybor, A., and Weichselbaum, R. (1989). Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor prognosis head and neck cancer: a phase I-II study. J. Clin. Oncol. 7, 761-768.
34. Whitney, C., Sause, W., Bundy, B., Malfetano, J., Hannigan, E., Fowler, W., Clarke-Pearson, D., and Liao, S. (1999). Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J. Clin. Oncol. 17, 1339-1348.
35. Xue, L., Zhou, B., Liu, X., Qiu, W., Jin, Z., and Yen, Y. (2003). Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 63, 980-986.
36. Yamaguchi, T., Matsuda, K., Sagiya, Y., Iwadate, M., Fujino, M., Nakamura, Y., and Arakawa, H. (2001). p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 61, 8256-8262.
37. Zhu, L., Zhou, B., Chen, X., Jiang, H., Shao, J., and Yen, Y. (2009). Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicarbazones for two forms of human ribonucleotide reductase. Biochem. Pharmacol. 78, 1178-1185.